💰 Dividend History

No dividend history available.

📅 Earnings & EPS History for PELI

No earnings history available for this symbol.

📰 Related News & Research

• Sichuan Biokin Pharmaceutical Hong Kong IPO: Innovative Oncology Pipeline, Growth Strategies & Global Expansion (2025 Prospectus Highlights)
  January 17, 2026
  

  Baili Pharmaceutical: Hong Kong IPO Analysis, Offer Details, Financials & Outlook Baili Pharmaceutical Co., Ltd. Date of Prospectus: November 7, 2025 Baili Pharmaceutical’s Hong Kong…

• Soilbuild Construction Group Targets S$1bn Order Book by End-2026 With Strong Pipeline and Higher Dividend Potential 1
  January 16, 2026
  

  Broker: CGS InternationalDate of Report: January 15, 2026 Excerpt from CGS International report. Report Summary Soilbuild Construction Group (SBCG) maintains a strong S\$1bn tender book…

• Suzhou Ribo Life Science IPO: Leading the Future of siRNA Oligonucleotide Therapeutics – Company Overview, Pipeline, and Competitive Edge 1116272278
  January 4, 2026
  

  Suzhou Ribo Life Science Co., Ltd. IPO: Investor Analysis & Outlook Suzhou Ribo Life Science Co., Ltd. Date of prospectus: December 31, 2025 Suzhou Ribo…

• Hanx Biotech IPO Prospectus 2025: Innovative Cancer & Autoimmune Drug Pipeline, Key Products HX009, HX301, HX044, Investment Highlights & Market Opportunities
  December 20, 2025
  

  Hanx Biopharmaceuticals (Wuhan) Co., Ltd. IPO Analysis – December 15, 2025 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Date of prospectus: December 15, 2025 Hanx Biopharmaceuticals Pre-Revenue…

• Innovative PDGF Drug Developer Huarenshengwu: Pipeline, Market Strategy, and IPO Prospectus Overview
  December 20, 2025
  

  B&K Corporation Limited IPO: In-Depth Analysis for Investors B&K Corporation Limited Date of Prospectus: December 12, 2025 B&K Corporation Limited’s Landmark Hong Kong IPO: Deep…

• Shanghai Bao Pharmaceuticals IPO: Innovative Biologics, Pipeline, and Commercial Strategy Explained
  December 6, 2025
  

  Bao Pharmaceuticals Co., Ltd. IPO Analysis – Offer Structure, Financial Performance, Growth Strategy & Listing Outlook Company Name: Bao Pharmaceuticals Co., Ltd. Date of Prospectus:…

• Innovative Biopharmaceutical Company Launches First Long-Acting Recombinant FSH-CTP (SJ02) in China, Advances Synthetic Biology Drug Pipeline and Global Expansion 10344351375
  December 6, 2025
  

  Shanghai Bao Pharmaceuticals Co., Ltd. – 2025 Hong Kong IPO Analysis, Growth Prospects, and Investor Outlook Shanghai Bao Pharmaceuticals Co., Ltd. Date of Prospectus: December…

• Xuanzhu Biopharma IPO: Innovative Drug Pipeline, Commercialization Strategy, and Competitive Advantages in China’s Pharmaceutical Market
  October 11, 2025
  

  Xuanzhu Biopharma IPO Analysis: Offer Details, Financials, Risks, and Outlook (October 2025) Xuanzhu Biopharma Date of Prospectus: October 6, 2025 Xuanzhu Biopharma Launches Hong Kong…

• Fujian Haixi Pharmaceuticals IPO: Innovative Drug Pipeline, Market Position & Growth Strategies Explained
  October 11, 2025
  

  HX Pharma IPO: Comprehensive Investor Analysis – October 2025 HX Pharma Date of Prospectus: October 9, 2025 Bold Bet on Future Growth: HX Pharma’s Landmark…

• Digital Core REIT Investor Presentation September 2025: Pure-Play Data Centre S-REIT, Global Growth Pipeline, and Sustainable Expansion Strategies 363839
  September 9, 2025
  

  “Digital Core REIT’s \$15 Billion Growth Ambition: AI Wave, Sponsor Backing, and High-Quality Assets Power Up Shareholder Value” Digital Core REIT Sets Stage for Explosive…

🔍 View more Reports